Asahi shares mark weekly slide after cyberattack halts production
Revvity Inc stock reached a new 52-week low, hitting 85.01 USD. According to InvestingPro data, the company maintains strong fundamentals with a perfect Piotroski Score of 9 and a "GOOD" overall financial health rating. This milestone reflects a significant downturn for the company, which has seen its stock value decrease by 25.3% over the past year. The decline underscores ongoing challenges for Revvity Inc in maintaining investor confidence amid market fluctuations. Despite the current price weakness, analysts maintain optimistic targets ranging from $100 to $162 per share. As the stock touches this new low, stakeholders may be prompted to reassess their strategies and outlooks for the company’s future performance. InvestingPro analysis suggests the stock is currently undervalued, with 8 additional exclusive insights available to subscribers through the comprehensive Pro Research Report.
In other recent news, Revvity Inc. reported its second-quarter 2025 earnings, surpassing analyst expectations with an adjusted earnings per share of $1.18, compared to the forecasted $1.14. The company’s revenue also exceeded projections, reaching $720 million against the anticipated $710.39 million. Despite these positive results, several analyst firms have adjusted their price targets for Revvity. Stifel lowered its price target to $110, maintaining a Hold rating, citing pressures from China’s ImmunoDx market. Raymond James also reduced its target to $115, pointing to reimbursement challenges in China affecting growth. Similarly, Bernstein adjusted its target to $115 while noting the company’s organic growth aligned with consensus estimates. Jefferies decreased its target to $100, referencing concerns over China’s drug-related group policies impacting Revvity’s financial outlook. These developments reflect a cautious stance among analysts despite the company’s better-than-expected earnings performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.